MODULAR STIMULUS APPLICATOR SYSTEM AND METHOD
20200345537 ยท 2020-11-05
Inventors
Cpc classification
A61N1/0476
HUMAN NECESSITIES
A61N1/0428
HUMAN NECESSITIES
A61N1/0456
HUMAN NECESSITIES
A61H2201/10
HUMAN NECESSITIES
A61H2201/5028
HUMAN NECESSITIES
A61H2230/505
HUMAN NECESSITIES
A61H1/00
HUMAN NECESSITIES
International classification
A61F7/00
HUMAN NECESSITIES
A61H1/00
HUMAN NECESSITIES
Abstract
A modular stimulus applicator system and method are disclosed. The system includes a plurality of wirelessly controlled stimulus pods, anchored to a patient's body, and configured to deliver stimulus to the patient's body. The stimulus can be heat, vibration, or electrical stimulus, or any combination thereof. The stimulus pods are controlled by a control station that can include a user-interface through which the patient can control application of the stimulus.
Claims
1-6. (canceled)
7. A therapeutic stimulus application system, comprising: a plurality of stimulus pods, individual stimulus pods comprising a battery, a first communication link, and a stimulus delivery surface for application to selected portions of a human body through which stimulus is applied to the portions of the human body; a base comprising a plurality of sockets configured to receive the stimulus pods, wherein the individual sockets comprise a power transmission mechanism through which electrical power is transferred to the battery of individual stimulus pods when the stimulus pods are positioned in the socket; and a control station comprising a second communication link configured to communicate with the first communication link of individual stimulus pods, and an input device through which input commands are received, wherein the control station instructs the stimulus pods to deliver the stimulus to the human body according to the input commands.
8. The therapeutic heat application system of claim 7 wherein the control station and the base are part of a single unit.
9. The therapeutic heat application device of claim 7 wherein individual stimulus pods comprise a disk-shaped device approximately one inch in diameter, and wherein the stimulus pods are held to the human body by an anchor.
10. The therapeutic stimulus application system of claim 7 wherein the plurality of stimulus pods comprises at least one index stimulus pod and at least one dummy stimulus pod, and wherein the index stimulus pod is configured to communicate between the dummy stimulus pod and the control station.
11. The therapeutic stimulus application system of claim 7 wherein the stimulus comprises heat, the system further comprising a thermal limiter comprising at least one temperature sensor, the thermal limiter being in communication with the plurality of stimulus pods to instruct the stimulus pods to cease applying heat if the temperature sensor detects a temperature above a predetermined threshold temperature.
12. The therapeutic stimulus application system of claim 11 wherein the thermal limiter comprises a thermal fuse that interrupts power to the stimulus delivery surface if the temperature sensor detects a temperature above the predetermined threshold temperature.
13. The therapeutic stimulus application system of claim 7 wherein the control station comprises a portable electronic device.
14. The therapeutic stimulus application system of claim 7 wherein the power transmission mechanism comprises an induction charger, and wherein the stimulus pods comprise an induction charge receiver that transfers energy from the induction charger to the battery.
15. The therapeutic stimulus application system of claim 7 wherein the power transmission mechanism comprises a conductive charger, and wherein the stimulus pods comprise a jack for connection to the conductive charger.
16. The therapeutic stimulus application system of claim 7, further comprising a memory for storing a sequence of operations for the stimulus pods.
17. The therapeutic stimulus application system of claim 16 wherein the sequence of operations comprises a combination of ramp up operations, maximum stimulus intensity operations, ramp down operations, stimulus soak operations, and lockout period operations.
18. The therapeutic stimulus application system of claim 17 wherein: the ramp up operations comprise gradually increasing a temperature applied through the heating surface of the stimulus pods; the maximum stimulus intensity operations comprise maintaining the stimulus at a predetermined maximum energy level; the ramp down operations comprise gradually decreasing the stimulus; the stimulus soak operations comprise maintaining the stimulus at a predetermined soak stimulus level below the predetermined maximum energy level; and wherein the lockout period operations comprise interrupting stimulus from the stimulus pods.
19. The therapeutic stimulus application system of claim 17 wherein the input device receives a selection from between ramp up operations, maximum temperature operations, ramp down operations, temperature soak operations, and lockout period operations.
20. The therapeutic stimulus application system of claim 17 wherein the stimulus pods execute the lockout period for a predetermined time interval in response to at least one of: a temperature exceeding a predetermined threshold temperature; an energy delivery level exceeding a predetermined threshold energy delivery level; and the stimulus applying stimulating the heating surface for more than a predetermined time threshold.
21. A method, comprising locating a plurality of wireless stimulus pods relative to a patient's body; determining a treatment plan for stimulus delivery to the patient's body through the stimulus pods, including at least one of a ramp up operation, a ramp down operation, a stimulus soak operation, and a lockout period; and receiving operator input directing application of the stimulus to the plurality of stimulus pods, including a selection from among the ramp up operation, the ramp down operation, the stimulus soak operation, and the lockout period; and instructing the stimulus pods to deliver the stimulus according to the treatment plan and the operator input.
22. The method of claim 21 wherein locating the plurality of wireless stimulus pods comprises wirelessly receiving an indication of location from the stimulus pods at a control station.
23. The method of claim 21 wherein receiving the operator input comprises receiving input through a user-interface of a control station, and wherein instructing the stimulus pods comprises instructing the stimulus pods from a control station to deliver the stimulus.
24. The method of claim 21 wherein the stimulus comprises at least one of heat, vibration, and electrical stimulus.
25. The method of claim 21, further comprising detecting an energy delivery level and comparing the energy delivery level to a predetermined threshold, wherein the lockout period is applied if the energy delivery level exceeds the predetermined threshold.
26. The method of claim 25 wherein the stimulus comprises at least one of heat, vibration, and electrical stimulus, and wherein the predetermined threshold includes a first threshold for heat, a second threshold for vibration, and a third threshold for electrical stimulus.
27. The method of claim 25 wherein the stimulus is heat, the method further comprising detecting a temperature of the stimulus pods, and wherein the lockout period continues until the temperature of the stimulus pods falls below a predetermined threshold temperature.
28. The method of claim 21 wherein the lockout period is triggered after the stimulus has been continually applied for more than a predetermined threshold time.
29. The method of claim 21, further comprising positioning the stimulus pods on the patient's body on or near a source of pain.
30. The method of claim 21 wherein locating the wireless stimulus pods and instructing the stimulus pods comprises communicating from a base station to an index stimulus pod and from the index stimulus pod to at least one dummy stimulus pod.
31. The method of claim 21 wherein locating the plurality of wireless stimulus pods relative to the patient's body comprises determining an area of the patient's body directly contacted by a stimulus pod, and determining an area of effect not directly contacted by the stimulus pod but within an effective region of the stimulus pod.
32. The method of claim 31 wherein the area of effect varies according to positions on the patient's body.
33. The method of claim 31 wherein the size of the area of effect is generally inversely proportional to a nerve density of the patient's body contacting the stimulus pod.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0012]
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
DETAILED DESCRIPTION
[0030] The present disclosure is directed generally to apparatuses, devices and associated methods for applying heat to various parts of the human body using a series of modular pods. The pods can be controlled by a remote controller in the form of a computer (a desktop or a laptop computer), or a mobile device such as a mobile phone, tablet or MP3 player. The pods can releasably attach to disposable rings that adhere to the body at various locations to which the patient desires to direct heat therapy.
[0031] Several details describing thermal and electrical principles are not set forth in the following description to avoid unnecessarily obscuring embodiments of the disclosure. Moreover, although the following disclosure sets forth several embodiments of the invention, other embodiments can have different configurations, arrangements, and/or components than those described herein without departing from the spirit or scope of the present disclosure. For example, other embodiments may have additional elements, or they may lack one or more of the elements described below with reference to
[0032]
[0033] The stimulus pods 110 can also be used to deliver medicine to a patient through electrophoresis or iontophoresis. Electrophoresis is the motion of dispersed particles relative to a fluid under the influence of a spatially uniform electric field. Electrophoresis is ultimately caused by the presence of a charged interface between the particle surface and the surrounding fluid. Iontophoresis (a.k.a. Electromotive Drug Administration (EMDA)) is a technique using a small electric charge to deliver a medicine or other chemical through the skin. It is basically an injection without the needle. The technical description of this process is a non-invasive method of propelling high concentrations of a charged substance, normally a medication or bioactive agent, transdermally by repulsive electromotive force using a small electrical charge applied to an iontophoretic chamber containing a similarly charged active agent and its vehicle. One or two chambers are filled with a solution containing an active ingredient and its solvent, also called the vehicle. The positively charged chamber (anode) will repel a positively charged chemical, whereas the negatively charged chamber (cathode) will repel a negatively charged chemical into the skin.
[0034]
[0035]
[0036]
[0037]
[0038] Any of the attachment mechanisms provide a simple way for a patient to apply a stimulus pod 110 to their body. The stimulus pods 110 can be interchangeable between anchors 120, and vice versa. A patient can use a stimulus pod 110 until the battery is depleted, and then simply swap in another stimulus pod 110 with a fresh battery. The attachment means can be strong enough and the dimensions of the stimulus pod 110 can be small enough that the stimulus pod 110 can be worn under the patient's clothing easily. The placement of the anchors 120 can vary greatly according to a predetermined diagnostic pattern or personal preference. In some embodiments, the stimulus pods 110 can be placed at an area of discomfort, such as a painful lower back. Some research suggests that placing additional stimulus pods 110 at an area remote from a problem area can also provide analgesic effects. For example, a patient may use a stimulus pod 110 at the lower backwhere the pain isbut they can also use a secondary stimulus pod 110 near the shoulders or on the legs. Multiple stimulus pods 110 can be used in concert to produce an aggregate affect. As different areas of the human body have different nerve densities, in certain areas two stimulus pads 110 placed near one another are perceived as a single, large stimulus pad 110. For example, the patient's back has much lower nerve density than the face, neck, or arms. Accordingly, the patient can use a pair of small stimulus pads 110 (e.g., one or two inches in diameter) at the lower back spaced about three or four inches apart and achieve the same sensory result as a larger stimulus pad covering the entire area. An unexpected benefit of this arrangement is that much less power is required to provide the stimulus in two small areas than would be required to stimulate the entire area.
[0039]
[0040] The charging station 200 can include a light 225 that can indicate that the charging station 200 is transmitting power to a stimulus pod 110. When the battery 155 of the stimulus pod 110 is fully charged, the stimulus pod 110 can notify the charging station 200 which can then cease charging the battery 155 and change the light 225 to indicate that the battery 155 is fully charged and is ready for use. When there are several stimulus pods 110 having different power levels in different sockets 205, the charging station 200 can charge the stimulus pods 110 that have less than a full charge while not powering the stimulus pods 110 that have a more full charge.
[0041]
[0042]
[0043] In several embodiments, the stimulus pods 110 can communicate with a control station 230, shown schematically in
[0044] In several embodiments, the control station 230 can have information regarding the location of the stimulus pods 110 on the patient's body, and can vary the stimulus pattern accordingly. In one embodiment, the stimulus pods 110 can be built with certain body positions in mind. The stimulus pods 110 can carry body position labels to instruct the patient to apply the stimulus pods 110 according to the label. For example, in a set of four stimulus pods, two can be marked shoulders, a third can be marked lower back, and a fourth can be marked upper back. In some embodiments, the anchors can communicate its location to the stimulus pod 110. The anchor 120 can include a passive identifier such as an RFID tag or other simple, passive method of communicating with the stimulus pod 110. In this embodiment, the anchor 120 can remain in place even when different stimulus pods 110 are swapped in and out of the anchor 120. The stationary anchor 120 can accurately provide location information to the control station 230 independent of which specific stimulus pod 110 occupies the anchor 120.
[0045] In other embodiments, the patient can inform the control station 230 where the stimulus pods 110 are situated, and with this information the control station 230 can apply the desired stimulus pattern to the stimulus pods 110. For example, the stimulus pods 110 can fire sequentially, and the patient can indicate the location of the stimulus on a user interface. Through the user interface, the patient can also operate the system 100 and apply treatment. In one embodiment, a control station 230 that comprises a smart phone or a computer, a graphic depiction of the patient's body can be shown and the patient can indicate to the control station 230 where the stimulus pods 110 are located. Alternatively, the patient can directly control the stimulus application through the stimulus pods 110 by moving a pointing device along the graphical depiction of their body to create a virtual stimulus-massage that the patient, or a healthcare professional, controls directly. In some cases the control station 230 can include a touch screen that the patient can touch to apply heat or other stimulus to various portions of their body (or to the body of another patient).
[0046]
[0047] In some embodiments, the index pod 110a and control station 230 can discern when two or more stimulus pods 110 (e.g., dummy pods 110b or index pods 110a) are near enough to one another that they can work in aggregate. If the control station 230 knows where the stimulus pods 110 are placed on the patient's body, the control station 230, through the index pods 110a, can vary the threshold distance between stimulus pods 110a, 110b as a function of nerve density at different locations on the body. For example, if the control station 230 discerns that two or more dummy and/or index pods 110a, 110b are three inches apart and on the lower back, the control station can operate the stimulus pods 110a, 110b together to effectively cover the area between the stimulus pods 110a, 110b as well as the area directly contacting the stimulus pods 110a, 110b. By comparison, if stimulus pods 110a, 110b are three inches apart, but are placed on a more sensitive area, such as the patient's face or neck, the control station 230 can determine that the aggregate effect may not be perceived to reach the area between the stimulus pods 110a, 110b because of the greater nerve density. This information can be used when applying a treatment plan that calls for stimulus on a prescribed area. The control station can determine whether there is a stimulus pod 110 on or near the prescribed area, and if not, whether the aggregate effect from two or more stimulus pods 110 can be used to carry out the treatment plan, and can execute the plan through the pods 110.
[0048] Several clinical studies were performed to evaluate effectiveness of the stimulus pod system. Details of the clinical studies and the results are provided below.
[0049] Study of Characteristics of Thermal Analgesia in Human Subjects
[0050] A stimulus pod system for the clinical study was designed and built to optimize heat levels, intermittency and distribution. The stimulus pod system included a software controller, a set of instructions on a laptop computer and a hardware interface that connected a variety of stimulus pods to the laptop controller. A person skilled in the art would know that many types of controllers and interfaces could be used for the modular stimulus applicator system including, for example, off-shelf dedicated controllers and a software based controller on a smart phone or a tablet computer connected through a wireless or wired interfaces to the stimulus pod system. The software controller was used to control thermal variables. These variables include:
[0051] maximum temperature ( C.) of the high heat cycle (T-max);
[0052] rate of temperature climb ( C./seconds) for the initial heat cycle (T1-Ramp-up);
[0053] duration of T-max (seconds) (T-max time);
[0054] rate of temperature reduction ( C./seconds) to the baseline soak temperature (Ramp-down). There was no active cooling, so the Ramp-down time was a passive variable;
[0055] minimum temperature ( C.) of the low heat cycle (T-soak);
[0056] duration of T-soak (seconds) (T-soak time);
[0057] rate of temperature climb ( C./seconds) for the subsequent heat cycle (T2-Ramp-up);
[0058] wave forms of both the high heat (T-max) and low heat (T-soak) cycles (a square wave form or a saw tooth pattern). The temperature difference between the peak and valley of the saw tooth heat waves was controllable;
[0059] time (in seconds) from the beginning of one ramp up period to the beginning of the next ramp up period (Heat cycle); and
[0060] time (in minutes) of a number of sequential heat cycles (demand cycle).
[0061] The control laptop was connected via a USB port to a heating interface unit. This interface allowed controlling one to four stimulus pods. The pods had electrical resistance pads with embedded thermistors, which allowed for very tight control of temperature. The study initially utilized three sizes of stimulus pods: small (0.50.5 inches), medium (11 inches) and large (1.51.5 inches). The stimulus pods were connected to the heating interface unit with 8 ft long cables that allowed test subjects to move about the testing station.
[0062] The protocol was initially tested on 10 in-house subjects. Afterwards, a total of 23 outside subjects completed the entire initial protocol which was done in one 90 minute session. The results of the in-house testing were similar to the formal trial results. Within the group of 23 test subjects, 14 were females (61%) and 9 males (39%) with a mean age of 31 years (range 17-59, standard deviation9.9 years). The subjects were given explanation about the study procedure and study device. In an initial subset of subjects, each subject tried three different sizes of stimulus pods (small, medium, large) to determine what size was preferred for the subsequent phases of the study. The midsize stimulus pod was strongly preferred, and was used for the subsequent studies. In some instances, the subjects could not determine if the smallest pad was even heating. Also, there was no preference among the subjects for heating a larger area of the body by using a larger size (1.51.5 inches) stimulus pods.
[0063] Furthermore, a study was done to determine whether the subjects preferred a temperature above that which can be produced by a ThermaCare pad. Clinical observation indicated that many people who use heat as a therapy prefer temperatures which are in fact hot enough to cause hypertrophic changes of the underlying skin. These temperatures are most commonly obtained using electrical heating pads. Commercially available chemical heating pads, e.g., ThermaCare, can provide temperature only up to 40 C. The subsequent clinical observations indicated that this temperature limited the therapeutic effectiveness of chemical heating pads.
[0064] Once a subject's preferred temperature profile was determined, the subject was fitted with a variety of stimulus pods, and locations and the preferences were recorded. It was observed that the subjects were able to detect a difference in heat pulses of less than 1 C. As explained in more detail below, the subjects preferred a temperature that was significantly warmer (44.7 C.) than the 40 C. provided by ThermaCare.
[0065] The initial testing was done to determine the preferred temperature of the stimulus pods. The heating started at 41 C. for two minutes duration and then gradually increased in the 0.5 C. increments up to either a maximum temperature of 50 C. or until the subject felt that the pads were too hot. The initial ramp-up (T1-Ramp-up) was also varied and evaluated for the subject preference.
[0066] The temperature preferences and ratings were quantified using a thermal sensation scale that progressed from very cold, cold, slightly cool, neutral, slightly warm, warm, hot, to very hot. As shown in
[0067] It was also observed that some subjects liked an additional pod placed on their body distant to the area that was painful. This is likely just a distraction effect, but it still increased the effectiveness of the heating pod that was placed over the body part in pain.
[0068] In summary, this study systematically evaluated properties of heat that are likely to relate to thermal analgesia. The subjects preferred temperatures that were significantly hotter than the 40 C., which can be provided by chemical heat packs such as, for example, ThermaCare. The actual or optimal temperature preferred by the subjects varied and approached a bell shaped distribution. Initially, it was assumed that the small size heating pods (0.50.5 inches) or the large size heating pods (1.51.5 inches) would be preferred by subjects. However, the medium size pads were the most preferred. It is possible that the small pads were too small to optimally stimulate the cutaneous thermal receptive fields. In many instances when subjects were asked how large of an area was being stimulated both the medium and large pods produced a heated area that was similar in size. In most instances once the pods were removed, subjects continued to report that the skin still felt as if it was being heated. Furthermore, in several subjects with a painful area of the body not being heated e.g., neck, reported that this proximal unheated area felt better when a distant area e.g., low back was heated.
[0069] The above clinical study demonstrated a dose response in the subjects. There is also a distinct fall-off as temperatures increase above 45-46 C. The distribution is relatively tight, and it provides little margin for error with analgesic devices, such as chemical hot packs with poorly controlled or too low temperature. Furthermore, it is possible that heat pulses may provide more stimulation of the cutaneous receptors in comparison to a steady heat wave.
[0070] Study of Heat Treatment of Premenstrual Syndrome (PMS) Pain
[0071]
[0072] The hypothesis of this study was that a high level pulsed heat would be more effective than a low level continuous heat in relieving pain associated with PMS. The study compared analgesic effects of the stimulus pod system as in this invention with those of a commercially available ThermaCare wrap. The stimulus pod system consisted of two heating pads that can be set to a temperature selected by the individual subject. The temperature range of the heater could be set between and including 42 to 47 C. The ThermaCare wrap is a commercial product available over the counter. The ThermaCare wrap is attached to the skin using its own elastic wrap. ThermaCare heats at a steady 40 C.
[0073] All subjects met with a research assistant (RA) prior to the start of the study. The RA explained and demonstrated the heating devices operation, their purpose and the methods of the study. The subjects were randomly assigned to one of two groups: the stimulus pod system or the ThermaCare group. All subjects completed a brief questionnaire about their pain. The study flow is illustrated in
[0074] Subjects rated their PMS pain level using Numeric Pain Scale and Iowa Pain Thermometer. Those subjects who were initially assigned to the ThermaCare had the device placed over their area of greatest pain (anterior abdomen or lower back). ThermaCare devices were allowed to warm up at least 30 minutes before being placed on the subject. Subjects rated their pain levels at baseline (time zero) and after 10, 20 and 30 minutes. After the first treatment session there was a 30 minute washout period.
[0075] Those subjects who were assigned to the stimulus pod system group were shown the study device. The RA facilitated a run-in period in which the subjects were able to gradually increase the temperature of the heating pads starting at 42 C. up to a maximum of 47 C. Once the subjects selected study temperature, the subjects wore the stimulus pod system and provided pain assessments at baseline and after 10 minutes, 20 minutes and 30 minutes. After completing the study subjects filled out an exit interview questionnaire and were paid for their participation.
[0076]
[0077]
[0078] In conclusion, both treatments produced significant reduction in pain in the subjects suffering from PMS pain. When compared to ThermaCare, the stimulus pod system produced significantly higher pain relief. In the exit interviews, the subjects almost unanimously noted that they all preferred the warmer temperatures from the stimulus pod system than those offered by the low level heat of the ThermaCare product. Many subjects also explained that they very much liked the pulsing sensation provided by the Heater device.
[0079] Study of Heat Treatment of Low Back Pain (LBP)
[0080]
[0081] Heat has long been a mainstay treatment for low back pain. A number of recent studies demonstrated that heat reduces low back pain, improves function and may result in the use of fewer pain medications. In spite of both empiric evidence and formal studies little is known about mechanisms or dose response data for heat induced LBP relief. The hypothesis of this study was that a high level pulsed heat would be more effective than a low level continuous heat in relieving chronic low back pain.
[0082] The subjects used the stimulus pod system or ThermaCare as explained above in relation to the Study of Heat Treatment of Premenstrual Syndrome Pain. Those subjects who were randomized initially to the stimulus pod system group were shown the study device. The RA facilitated a run in period in which the subject was able to gradually increase the temperature of the heating pads starting at 42 C. up to a maximum of 47 C. Once the study temperature was selected, subjects wore the device and provided pain assessments at baseline and after 10 minutes, 20 minutes, and 30 minutes. After completing the study, all subjects filled out an exit interview questionnaire and were paid $100 for study participation.
[0083] As shown in
[0084]
[0085] In conclusion, both treatments (the stimulus pod system and ThermaCare) produced reduction in pain in the subjects who suffered from chronic low back pain. The stimulus pod system produced significantly higher pain relief in comparison to ThermaCare. The higher heat provided by the stimulus pod system was associated with better and more profound pain relief. In the exit interviews, subjects almost unanimously noted that they all preferred the warmer temperatures from the stimulus pod system than that offered by the low level heat of the ThermaCare product. Many subjects also stated that they very much liked the pulsing sensation provided by the Heater device.
[0086] From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the various embodiments of the invention. Further, while various advantages associated with certain embodiments of the invention have been described above in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the invention. Accordingly, the invention is not limited, except as by the appended claims.